🧬 biology

Molecular basis for allosteric regulation of RyR1 channel gating: effects of a therapeutic drug and oxidation-mimicking mutation

This study utilizes extensive all-atom molecular dynamics simulations to reveal that the therapeutic drug ARM210 stabilizes the RyR1 channel in a closed state by disrupting a long-range allosteric network linking the RY1&2 domain to the pore, a regulatory mechanism that is compromised by the oxidation-mimicking C3892D mutation.

Original authors: Karissa Sanbonmatsu, Jigneshkumar Prajapati, Marco Miotto, Jeevan GC, Haikel Dridi, Qi Yuan, Anetta Wronska, Yang Liu, Zephan Melville, Andrew Marks, Joachim Frank

Published 2026-11-03

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Karissa Sanbonmatsu, Jigneshkumar Prajapati, Marco Miotto, Jeevan GC, Haikel Dridi, Qi Yuan, Anetta Wronska, Yang Liu, Zephan Melville, Andrew Marks, Joachim Frank

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Inside every skeletal muscle fiber lies a vast network of microscopic storage tanks, the sarcoplasmic reticulum, which holds a reservoir of calcium ions. These ions are the essential fuel for movement; when a nerve signal tells a muscle to contract, the storage tanks must release their calcium cargo into the surrounding cell fluid. The gatekeepers of this release are massive protein channels called ryanodine receptors, specifically the RyR1 type found in skeletal muscle. These channels are enormous, complex machines that must open and close with perfect timing. If they open too easily or stay open when they should be shut, calcium leaks out uncontrollably. This leak deprives the muscle of its fuel, leading to weakness, fatigue, and a group of diseases known as RyR1-related myopathies. Scientists have long known that these channels can be damaged by oxidative stress, a form of cellular wear and tear, and that certain drugs called Rycals can help seal the leak. However, the exact molecular mechanics of how these drugs work, and how damage at one tiny spot can cause the entire massive machine to malfunction, have remained hidden in the fog of atomic complexity.

A team of researchers has now peeled back this fog using a combination of advanced computer modeling and laboratory experiments to reveal the inner workings of the RyR1 channel. They focused on a specific therapeutic drug, ARM210, which has shown promise in clinical trials for treating muscle diseases, and a specific mutation that mimics the damage caused by oxidative stress. By simulating the movement of every single atom in the channel—totaling about 2.5 million atoms—over a period of time equivalent to 36.6 microseconds, the team constructed a dynamic movie of the channel's behavior. This allowed them to watch how a signal travels from the outer edge of the protein to its central gate, and how a drug or a mutation alters that journey.

The researchers discovered that the RyR1 channel operates through a long-range communication system, a sort of molecular relay race that spans more than 200 angstroms, a distance roughly 100 times the width of a single atom. In a healthy, functioning channel, a signal begins at the peripheral edge of the protein, where a specific domain known as the RY1&2 region acts like a lever. When this lever moves, it triggers a chain reaction of coordinated shifts and rotations that travel through the protein's cytosolic shell, down through the activation core, and finally reach the pore-forming helices at the center. This synchronized motion is what forces the central gate to open and release calcium. The simulations showed that without a stabilizing influence, this lever can swing open too freely, initiating the chain reaction that leads to a leaky channel.

The study revealed that the drug ARM210 works by acting as a molecular lock on this peripheral lever. When the drug binds to the RY1&2 domain, it freezes that region in a closed position. This rigidity prevents the lever from swinging, which in turn stops the chain reaction from starting. The drug effectively stiffens the entire outer shell of the protein, breaking the long-range communication network that would otherwise carry the signal to the central gate. As a result, even if other factors in the cell are trying to tell the channel to open, the gate remains shut, preventing the dangerous calcium leak. This finding provides a clear, atom-by-atom explanation for why the drug is effective, showing that it does not just plug a hole but stabilizes the entire machine's structure.

However, the researchers also found that this protective mechanism can be undermined by damage. They investigated a specific mutation, C3892D, which mimics the chemical changes that occur when the protein is exposed to oxidative stress. In the simulations, this mutation acted like a wrench thrown into the gears of the communication network. It disrupted the coordination between different parts of the protein, specifically pulling a key calcium-binding domain away from its partner. This misalignment caused the central gate to become unstable and prone to opening, even when the drug ARM210 was present. The drug could still lock the peripheral lever, but the damage at the mutation site had already severed the connection between the lock and the gate. The signal could no longer be properly transmitted, and the channel began to leak on its own.

These findings suggest that while drugs like ARM210 are powerful tools for stabilizing the RyR1 channel, their effectiveness depends on the integrity of the protein's internal communication network. If oxidative damage or mutations disrupt the specific pathways that carry the signal from the drug-binding site to the gate, the drug may lose its ability to hold the channel closed. The study highlights that the RY1&2 domain is a critical control point, but it is not an isolated switch; it is part of a vast, interconnected system. For future treatments, this implies that the most effective drugs might be those that not only bind tightly to the peripheral domain but also reinforce the structural connections throughout the protein, ensuring that the signal to stay closed is transmitted reliably even in the face of cellular damage. The work provides a detailed map of how a massive molecular machine functions and fails, offering a blueprint for designing the next generation of therapies to keep muscles strong and healthy.

Technical Summary: Molecular Basis for Allosteric Regulation of RyR1 Channel Gating

Problem Statement
The Ryanodine Receptor 1 (RyR1) is a massive (~2.2 MDa) tetrameric calcium-release channel in the skeletal muscle sarcoplasmic reticulum (SR), essential for excitation-contraction coupling. Dysregulation of RyR1, often caused by pathogenic mutations or post-translational modifications (such as oxidation), leads to aberrant SR Ca²⁺ leak, contributing to RyR1-related myopathies and other diseases. While the therapeutic drug ARM210 (a Rycal-class compound) has shown promise in stabilizing RyR1 and preventing Ca²⁺ leak in clinical trials, the atomistic mechanism by which ARM210, binding at the distal peripheral RY1&2 domain, allosterically stabilizes the channel pore in a closed state remains unclear. Furthermore, the impact of oxidative stress, specifically at cysteine residues near the Ca²⁺ activator site, on this allosteric network and drug efficacy requires elucidation.

Methodology
The study employed a multi-disciplinary approach combining experimental biophysics with extensive computational modeling:

Experimental Characterization:
- Mass Spectrometry: Purified RyR1 was treated with H₂O₂ to identify oxidized cysteine residues.
- Electrophysiology: Single-channel recordings in HEK293-derived microsomes measured open probability ( $P_o$ ) of wild-type (WT) and cysteine mutants (C3733A, C3892A, C3973A, C3892D) with and without H₂O₂.
- Live-Cell Fluorescence Microscopy: SR Ca²⁺ content was quantified in HEK293 cells expressing WT or mutant RyR1 under oxidative stress and ARM210 treatment.
- Mutagenesis: Site-directed mutagenesis was used to create alanine (loss-of-function) and aspartic acid (oxidation-mimicking) mutants.
Molecular Dynamics (MD) Simulations:
- System Scale: All-atom, explicit-solvent simulations of the full-length RyR1 tetramer (~2.5 million atoms).
- Conditions: Three distinct systems were simulated:
  1. WT RyR1 with cofactors (ATP, Ca²⁺, caffeine) but no drug.
  2. WT RyR1 with ARM210 and ATP bound to the RY1&2 domain.
  3. C3892D mutant RyR1 with ARM210 and ATP bound.
- Scale: Total simulation time reached 36.6 µs across 36.6 µs of aggregate time (using 25 million CPU hours on the Chicoma supercomputer).
- Analysis: Root Mean Square Deviation (RMSD), ligand occupancy, translational/rotational domain movements, and Pearson correlation matrices of domain motions were computed to map allosteric pathways.

Key Results

Identification of C3892 as a Redox Sensor: Mass spectrometry and functional assays identified C3892 as a critical residue mediating oxidation-induced Ca²⁺ leak. The C3892D mutation (mimicking oxidation) significantly increased basal $P_o$ and depleted SR Ca²⁺ stores, effects that were not observed in the C3892A mutant. ARM210 effectively prevented Ca²⁺ depletion in WT but showed reduced efficacy in the C3892D mutant context.
ARM210 Stabilizes the RY1&2 Domain: In the absence of ARM210, the peripheral RY1&2 domain undergoes a "jaw-like" opening (increasing the angle between residues E888, L1046, and V1001 from ~~50° to ~85°). ARM210 binding, cooperatively with ATP, rigidifies this domain, keeping it in a closed conformation (~~50°).
Long-Range Allosteric Pathway: In WT RyR1 without the drug, a correlated allosteric network was identified spanning >200 Å. Motions in the RY1&2 domain of one protomer propagate through the cytosolic shell 2 region, into the activation core, and ultimately to the pore-forming S6c helices of the adjacent protomer, facilitating pore dilation.
Mechanism of Drug Action: ARM210 binding disrupts this long-range network. While the drug-bound RY1&2 domain remains correlated with the immediate cytosolic shell 2, the correlation signal is dampened and fails to propagate effectively beyond the CSol domain of the activation core to the S6c helices. This "break" in the allosteric chain prevents the conformational changes necessary for pore opening, stabilizing the closed state.
Disruption by Oxidation-Mimicking Mutation: In the C3892D mutant, the allosteric network is further compromised. The mutation alters Ca²⁺ coordination, displacing the Ca²⁺ ion and destabilizing the interface between the CSol and CTD domains. This leads to exaggerated anticlockwise rotation and downward displacement of the CTD domain. Consequently, even with ARM210 bound, the S6c helices exhibit greater dilation than in the drug-bound WT, explaining the mutant's "leaky" phenotype and reduced drug efficacy.

Significance and Claims
The paper claims to provide the first atomistic description of how a therapeutic drug (ARM210) stabilizes the RyR1 channel in a closed state by modulating a long-range (>200 Å) allosteric pathway. The study demonstrates that:

Allosteric Mechanism: Drug binding at the distal RY1&2 domain prevents pore opening not by direct steric hindrance of the pore, but by rigidifying the cytosolic shell and disrupting the correlated motions required to transmit activation signals to the S6 helices.
Redox Sensitivity: The C3892 residue acts as a critical redox sensor; its oxidation (mimicked by C3892D) disrupts Ca²⁺ coordination and decouples the allosteric network, leading to pathological channel leakiness.
Therapeutic Implications: The findings suggest that the reduced efficacy of ARM210 in the C3892D mutant is due to the mutation-induced structural misalignment that bypasses the drug's stabilizing effect on the allosteric network. This highlights the need for next-generation Rycals that can more effectively stabilize the RY1&2 domain and potentially engage ATP-binding pockets to counteract oxidative damage.

The authors conclude that elucidating these specific allosteric pathways is critical for optimizing future RyR-targeted therapeutics, particularly for conditions involving oxidative stress and specific pathogenic mutations.

More like this